Amgen reports six-month MARITIME Phase 3 update and issues full-year 2026 revenue guidance of $38.2B–$39.4B

Amgen announced Q2 2026 results with MARITIME-1 and MARITIME-2 on track for early 2027 readouts. MariTide remained a key growth driver with additional Phase 3 trials in heart failure, kidney disease, cardiovascular outcomes, and sleep apnea progressing. Q2 revenue was $10.1 billion, a 10% increase year-over-year.